AnalystsAndres Y. MaldonadoAndres Y. Maldonado's Stock Forecasts
AnalystsAndres Y. Maldonado
Sectors:
Industries:
Analyst Ranking
Top 27%
#1376 out of 5087 analysts
Average Return
+16.12%
Win Rate
65%11 out of 17
Risk vs Reward
Poor
Good
Andres Y. Maldonado's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Monopar TherapeuticsMNPR | +169.00% | $32.03 | $86.16 | 2025-08-25 - 2025-10-31 | Buy |
Engene Holdings IncENGN | +32.78% | $5.43 | $7.21 | 2025-09-07 - 2025-10-31 | Buy |
Cg Oncology IncCGON | +30.84% | $33.07 | $43.27 | 2025-09-04 - 2025-10-31 | Buy |
Cg Oncology IncCGON | +28.44% | $33.69 | $43.27 | 2025-09-07 - 2025-10-31 | Buy |
Engene Holdings IncENGN | +26.27% | $5.71 | $7.21 | 2025-09-11 - 2025-10-31 | Buy |
Andres Y. Maldonado Analyst Color
Get additional color on Andres Y. Maldonado's coverage of popular stocks
Andres Y. Maldonado's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Syndax Pharmaceuticals IncSNDX | 2 | Buy | $40.00 | +191.97% | Reiterates | 5 days ago |
Corbus Pharmaceuticals Holdings IncCRBP | 2 | Buy | $40.00 | +229.22% | Reiterates | 12 days ago |
Merus NvMRUS | 1 | Hold | $97.00 | +2.26% | Downgrades | a month ago |
Candel Therapeutics IncCADL | 1 | Buy | $23.00 | +327.51% | Reiterates | a month ago |
Monopar TherapeuticsMNPR | 2 | Buy | $105.00 | +21.87% | Maintains | a month ago |
Scholar Rock Holding CorpSRRK | 1 | Buy | $44.00 | +48.55% | Maintains | a month ago |
Cg Oncology IncCGON | 3 | Buy | $75.00 | +73.33% | Reiterates | 2 months ago |
Engene Holdings IncENGN | 2 | Buy | $25.00 | +246.74% | Reiterates | 2 months ago |
Immunitybio IncIBRX | 1 | Buy | $8.00 | +233.33% | Reiterates | 2 months ago |
I MabIMAB | 1 | Buy | $7.00 | +41.41% | Reiterates | 2 months ago |
Aura Biosciences IncAURA | 1 | Buy | $22.00 | +258.89% | Reiterates | 3 months ago |
Keros Therapeutics IncKROS | 1 | Buy | $20.00 | +31.41% | Maintains | 3 months ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.